Herpes simplex virus type 2 tegument proteins contain subdominant T-cell epitopes detectable in BALB/c mice after DNA immunization and infection

被引:27
作者
Muller, William J. [1 ]
Dong, Lichun [2 ]
Vilalta, Adrian [3 ]
Byrd, Benjamin [2 ]
Wilhelm, Kai M. [2 ]
McClurkan, Christopher L. [4 ]
Margalith, Michal [3 ]
Liu, Chao [4 ]
Kaslow, David [3 ]
Sidney, John [5 ]
Sette, Alessandro [5 ]
Koelle, David M. [2 ,4 ,6 ,7 ,8 ]
机构
[1] Univ Washington, Dept Pediat, Div Pediat Infect Dis, Seattle, WA 98195 USA
[2] Univ Washington, Dept Med, Seattle, WA 98195 USA
[3] Vical Inc, San Diego, CA USA
[4] Univ Washington, Dept Lab Med, Seattle, WA 98195 USA
[5] La Jolla Inst Allergy & Immunol, Div Vaccine Discovery, La Jolla, CA USA
[6] Univ Washington, Dept Global Hlth Med, Seattle, WA 98195 USA
[7] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA
[8] Benaroya Res Inst, Seattle, WA USA
关键词
CONFERS PROTECTIVE IMMUNITY; FEMALE GENITAL-TRACT; GLYCOPROTEIN-D; MUCOSAL IMMUNITY; FLOW-CYTOMETRY; PEPTIDE; RESPONSES; RECOGNITION; LYMPHOCYTES; VACCINE;
D O I
10.1099/vir.0.008771-0
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Cytotoxic T cells are important in controlling herpes simplex virus type 2 (HSV-2) reactivation and peripheral lesion resolution. Humans latently infected with HSV-2 have cytotoxic T cells directed against epitopes present in tegument proteins. Studies in mice of immunity to HSV have commonly focused on immunodominant responses in HSV envelope glycoproteins. These antigens have not proved to be an effective prophylactic vaccine target for most of the human population. The murine immune response against HSV tegument proteins has not been explored. We analysed cellular responses in BALE/c mice directed against the tegument proteins encoded by UL46, UL47 and UL49 and against the envelope glycoprotein gD after DNA vaccination or HSV-2 infection. After DNA vaccination, the splenocyte T-cell response to overlapping peptides from UL46 and UL47 was more than 500 gamma interferon spot-forming units per 106 responder cells. Peptide truncation studies, responder cell fractionation and major histocompatibility complex binding studies identified several CD8(+) and CD4(+) epitopes. Cellular responses to tegument protein epitopes were also detected after HSV-2 infection. Tegument proteins are rational candidates for further HSV-2 vaccine research.
引用
收藏
页码:1153 / 1163
页数:11
相关论文
共 55 条
[1]   COMPARISON OF WESTERN BLOT (IMMUNOBLOT) AND GLYCOPROTEIN-G-SPECIFIC IMMUNODOT ENZYME ASSAY FOR DETECTING ANTIBODIES TO HERPES-SIMPLEX VIRUS TYPE-1 AND TYPE-2 IN HUMAN-SERA [J].
ASHLEY, RL ;
MILITONI, J ;
LEE, F ;
NAHMIAS, A ;
COREY, L .
JOURNAL OF CLINICAL MICROBIOLOGY, 1988, 26 (04) :662-667
[2]   RECOGNITION BY AND INVITRO INDUCTION OF CYTOTOXIC LYMPHOCYTES-T AGAINST PREDICTED EPITOPES OF THE IMMEDIATE-EARLY PROTEIN-ICP27 OF HERPES-SIMPLEX VIRUS [J].
BANKS, TA ;
NAIR, S ;
ROUSE, BT .
JOURNAL OF VIROLOGY, 1993, 67 (01) :613-616
[3]   The functional profile of primary human antiviral CD8+ T cell effector activity is dictated by cognate peptide concentration [J].
Betts, MR ;
Price, DA ;
Brenchley, JM ;
Loré, K ;
Guenaga, FJ ;
Smed-Sorensen, A ;
Ambrozak, DR ;
Migueles, SA ;
Connors, M ;
Roederer, M ;
Douek, DC ;
Koup, RA .
JOURNAL OF IMMUNOLOGY, 2004, 172 (10) :6407-6417
[4]   Immunization with a single major histocompatibility complex class I-restricted cytotoxic T-lymphocyte recognition epitope of herpes simplex virus type 2 confers protective immunity [J].
Blaney, JE ;
Nobusawa, E ;
Brehm, MA ;
Bonneau, RH ;
Mylin, LM ;
Fu, TM ;
Kawaoka, Y ;
Tevethia, SS .
JOURNAL OF VIROLOGY, 1998, 72 (12) :9567-9574
[5]   Automated generation and evaluation of specific MHC binding predictive tools:: ARB matrix applications [J].
Bui, HH ;
Sidney, J ;
Peters, B ;
Sathiamurthy, M ;
Sinichi, A ;
Purton, KA ;
Mothé, BR ;
Chisari, FV ;
Watkins, DI ;
Sette, A .
IMMUNOGENETICS, 2005, 57 (05) :304-314
[6]   Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection - Two randomized controlled trials [J].
Corey, L ;
Langenberg, AGM ;
Ashley, R ;
Sekulovich, RE ;
Izu, AE ;
Douglas, JM ;
Handsfield, HH ;
Warren, T ;
Marr, L ;
Tyring, S ;
DiCarlo, R ;
Adimora, AA ;
Leone, P ;
Dekker, CL ;
Burke, RL ;
Leong, WP ;
Straus, SE .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 282 (04) :331-340
[7]   The genome sequence of herpes simplex virus type 2 [J].
Dolan, A ;
Jamieson, FE ;
Cunningham, C ;
Barnett, BC ;
McGeoch, DJ .
JOURNAL OF VIROLOGY, 1998, 72 (03) :2010-2021
[8]   Induction of CD8 T-cell-specific systemic and mucosal immunity against herpes simplex virus with CpG-peptide complexes [J].
Gierynska, M ;
Kumaraguru, U ;
Eo, SK ;
Lee, S ;
Krieg, A ;
Rouse, BT .
JOURNAL OF VIROLOGY, 2002, 76 (13) :6568-6576
[9]   An improved plasmid DNA expression vector for direct injection into skeletal muscle [J].
Hartikka, J ;
Sawdey, M ;
CornefertJensen, F ;
Margalith, M ;
Barnhart, K ;
Nolasco, M ;
Vahlsing, HL ;
Meek, J ;
Marquet, M ;
Hobart, P ;
Norman, J ;
Manthorpe, M .
HUMAN GENE THERAPY, 1996, 7 (10) :1205-1217
[10]   Potent protective cellular immune responses generated by a DNA vaccine encoding HSV-2ICP27 and the E-coli heat labile enterotoxin [J].
Haynes, JR ;
Arrington, J ;
Dong, LC ;
Braun, RP ;
Payne, LG .
VACCINE, 2006, 24 (23) :5016-5026